ACADIA Pharmaceuticals Inc.ACADNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank82
3Y CAGR-20.9%
5Y CAGR-19.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-20.9%/yr
vs +62.6%/yr prior
5Y CAGR
-19.1%/yr
Consistent
Acceleration
-83.5pp
Decelerating
Percentile
P82
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 16.65% |
| Q3 2025 | -0.08% |
| Q2 2025 | 5.65% |
| Q1 2025 | -2.85% |
| Q4 2024 | -2.41% |
| Q3 2024 | 13.87% |
| Q2 2024 | 8.40% |
| Q1 2024 | -3.12% |
| Q4 2023 | 13.87% |
| Q3 2023 | 2.00% |
| Q2 2023 | -5.20% |
| Q1 2023 | -3.03% |
| Q4 2022 | 33.66% |
| Q3 2022 | -13.12% |
| Q2 2022 | -7.01% |
| Q1 2022 | -8.72% |
| Q4 2021 | 29.69% |
| Q3 2021 | -15.62% |
| Q2 2021 | -13.32% |
| Q1 2021 | -7.53% |
| Q4 2020 | 47.99% |
| Q3 2020 | -3.26% |
| Q2 2020 | -17.29% |
| Q1 2020 | 11.00% |
| Q4 2019 | 26.38% |
| Q3 2019 | 6.94% |
| Q2 2019 | -26.97% |
| Q1 2019 | 25.34% |
| Q4 2018 | 21.58% |
| Q3 2018 | -12.07% |
| Q2 2018 | 14.03% |
| Q1 2018 | -8.64% |
| Q4 2017 | 7.12% |
| Q3 2017 | 1.19% |
| Q2 2017 | -6.42% |
| Q1 2017 | 14.02% |
| Q4 2016 | 14.11% |
| Q3 2016 | -0.46% |
| Q2 2016 | 84.67% |
| Q1 2016 | 9.46% |